National Pension Service Has $46.89 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• The National Pension Service increased its holdings in Alnylam Pharmaceuticals by 8.9%, acquiring an additional 14,148 shares, bringing its total to 173,659 shares valued at approximately $46.89 million.
• An array of hedge funds have recently adjusted their positions in Alnylam Pharmaceuticals, with 92.97% of the stock now owned by institutional investors.
• Recent analyst upgrades have set new price targets for Alnylam Pharmaceuticals, with estimates ranging from $405.00 to $490.00, reflecting a consensus rating of "Moderate Buy."

National Pension Service raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 173,659 shares of the biopharmaceutical company's stock after buying an additional 14,148 shares during the period. National Pension Service owned about 0.13% of Alnylam Pharmaceuticals worth $46,891,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ALNY. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $243,000. Townsquare Capital LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $227,000. Mariner LLC increased its holdings in shares of Alnylam Pharmaceuticals by 16.6% during the fourth quarter. Mariner LLC now owns 13,666 shares of the biopharmaceutical company's stock worth $3,216,000 after buying an additional 1,947 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $364,000. Finally, Bridgewater Associates LP increased its holdings in shares of Alnylam Pharmaceuticals by 222.3% in the fourth quarter. Bridgewater Associates LP now owns 6,452 shares of the biopharmaceutical company's stock valued at $1,518,000 after purchasing an additional 4,450 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALNY. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a report on Friday, August 1st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a report on Friday, July 11th. Finally, Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a report on Friday, July 11th. Four investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $405.33.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 31,448 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director directly owned 911 shares in the company, valued at $397,724.38. The trade was a 97.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,385 shares of company stock worth $29,265,349 over the last quarter. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Up 1.8%

ALNY stock traded up $7.96 during midday trading on Monday, hitting $456.87. The company's stock had a trading volume of 1,398,881 shares, compared to its average volume of 950,400. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $457.92. The company's fifty day moving average price is $345.09 and its 200 day moving average price is $290.51. The stock has a market capitalization of $59.89 billion, a P/E ratio of -184.97 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion for the quarter, compared to analyst estimates of $633.54 million. During the same period in the previous year, the business earned ($0.13) EPS. The company's revenue was up 17.3% compared to the same quarter last year. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.